J Michael Ryan
Overview
Explore the profile of J Michael Ryan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caputo A, Racine A, Paule I, Tariot P, Langbaum J, Coello N, et al.
Alzheimers Res Ther
. 2023 Mar;
15(1):45.
PMID: 36879340
Background: There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer's disease...
2.
Tuncel H, Boellaard R, Coomans E, Hollander-Meeuwsen M, de Vries E, Glaudemans A, et al.
EJNMMI Res
. 2022 Jan;
12(1):3.
PMID: 35072802
[C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [C]UCB-J PET may serve as an in vivo marker of synaptic integrity. The main objective of...
3.
Rentz D, Wessels A, Annapragada A, Berger A, Edgar C, Gold M, et al.
Alzheimers Dement (N Y)
. 2021 Jul;
7(1):e12181.
PMID: 34195350
Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a...
4.
Tuncel H, Boellaard R, Coomans E, de Vries E, Glaudemans A, Feltes P, et al.
J Cereb Blood Flow Metab
. 2021 May;
41(6):1338-1350.
PMID: 34013797
[C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test-retest repeatability (TRT) of quantitative [C]UCB-J...
5.
Friedman L, McKeehan N, Hara Y, Cummings J, Matthews D, Zhu J, et al.
Neurology
. 2021 Mar;
96(20):944-954.
PMID: 33674360
Drug development for Alzheimer disease and other neurodegenerative dementias, including frontotemporal dementia, has experienced a long history of phase 2 and phase 3 clinical trials that failed to show efficacy...
6.
Coomans E, Schoonhoven D, Tuncel H, Verfaillie S, Wolters E, Boellaard R, et al.
Alzheimers Res Ther
. 2021 Feb;
13(1):35.
PMID: 33546722
Background: The mechanism of synaptic loss in Alzheimer's disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study,...
7.
Lopez C, Tariot P, Caputo A, Langbaum J, Liu F, Riviere M, et al.
Alzheimers Dement (N Y)
. 2019 Jun;
5:216-227.
PMID: 31211217
Introduction: Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive impairment. This long preclinical period provides an...
8.
Vandenberghe R, Riviere M, Caputo A, Sovago J, Maguire R, Farlow M, et al.
Alzheimers Dement (N Y)
. 2017 Oct;
3(1):10-22.
PMID: 29067316
Introduction: This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease. Methods: One hundred twenty-one patients received up to...
9.
Hull M, Sadowsky C, Arai H, Le Prince Leterme G, Holstein A, Booth K, et al.
Curr Alzheimer Res
. 2017 Jan;
14(7):696-708.
PMID: 28124589
Objectives: Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was evaluated in subjects with mild to moderate Alzheimer's disease. Design: Phase 2a extension studies of...
10.
Weiden P, Manning R, Wolfgang C, Ryan J, Mancione L, Han G, et al.
CNS Drugs
. 2016 Jul;
30(8):735-47.
PMID: 27379654
Background: The purpose of this study was to evaluate the safety and effectiveness of iloperidone for the prevention of relapse in schizophrenia. Methods: Study subjects were adults with schizophrenia who...